March 25, 2021

FORTUNE Names Dermavant One of the 2021 Best Workp ...

Read More

March 11, 2021

Dermavant Announces Tapinarof Data Presentation at ...

Read More

February 18, 2021

Positive Data from PSOARING 3 Support Long-Term Us ...

Read More

January 21, 2021

Dermavant Announces Tapinarof Data Presentation at ...

Read More

October 27, 2020

Dermavant’s Pivotal Phase 3 PSOARING Data for Ta ...

Read More

October 22, 2020

Dermavant Announces Presentation of Tapinarof Pivo ...

Read More

August 26, 2020

Dermavant Reports Positive Phase 3 Results for Tap ...

Read More

June 9, 2020

Dermavant Completes Patient Enrollment for Long-Te ...

Read More

May 26, 2020

Dermavant Announces Publication in JAAD of Seconda ...

Read More

April 2, 2020

Dermavant Completes Patient Enrollment for Two Pha ...

Read More

January 22, 2020

Dermavant Appoints Chris Chapman as Chief Commerci ...

Read More

January 15, 2020

Dermavant Enters into Exclusive License Agreement ...

Read More

December 3, 2019

Dermavant Announces First Patient Dosed in Phase 2 ...

Read More

June 5, 2019

Dermavant Sciences Announces First Patient Dosed i ...

Read More

May 15, 2019

Dermavant Sciences Appoints Timothy S. Nelson and ...

Read More

March 27, 2019

Dermavant Sciences Announces Appointment of Cyril ...

Read More

February 21, 2019

Dermavant Sciences to Present Data on Tapinarof fo ...

Read More

January 2, 2019

Dermavant Sciences Announces Appointment of Dr. Ph ...

Read More

December 6, 2018

Dermavant Sciences to Present New Data on Cerdulat ...

Read More

November 15, 2018

Dermavant Appoints Todd Zavodnick as Chief Executi ...

Read More